Literature DB >> 3316163

The role of the microbiology laboratory in the treatment of infective endocarditis.

C W Stratton1.   

Abstract

The antibiotic era has greatly improved the prognosis for patients with infective endocarditis. The need for bactericidal activity against the infecting organism has created an additional role for the clinical microbiology laboratory. This role involves the selection and performance of the proper in-vitro susceptible tests in order to ensure bactericidal activity. However, there are problems in both the performance and the interpretation of bactericidal tests; these include persisters, the 'paradoxical effect', tolerance and the development of resistance. Technical factors include inoculum size, growth phase of the inoculum, insufficient contact between the test organism and the antimicrobial agent, and the volume of transfer for the count of survivors. Appreciation of these factors is important for the laboratory performing bactericidal tests, which include time-kill curves, minimal bactericidal concentrations and the serum bactericidal test. Of these tests, the serum bactericidal test offers the most logical approach. However, the performance of this test and the interpretation of the results has been controversial. Recent attempts at standardization should allow better utilization. In addition to the serum bactericidal test, the clinical microbiology laboratory can offer time-kill curves and minimal bactericidal activity and can offer serum assays of antibiotics to ensure adequate levels without toxicity. The use of any or all of these methods must be tempered by clinical judgement in each individual case. Application of the proper tests can assist in the optimal therapy of infective endocarditis.

Entities:  

Mesh:

Year:  1987        PMID: 3316163     DOI: 10.1093/jac/20.suppl_a.41

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  7 in total

1.  Multiple breakpoint method for measuring effect of antibiotics on endocarditis strains of streptococci.

Authors:  J Marks; A Paull
Journal:  J Clin Pathol       Date:  1990-09       Impact factor: 3.411

2.  Effect of penicillin on endocarditis strains of viridans streptococci.

Authors:  J Marks; A Paull
Journal:  J Clin Pathol       Date:  1989-10       Impact factor: 3.411

Review 3.  Combination treatment of invasive fungal infections.

Authors:  Pranab K Mukherjee; Daniel J Sheehan; Christopher A Hitchcock; Mahmoud A Ghannoum
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

Review 4.  Penicillin tolerance and treatment failure in group A streptococcal pharyngotonsillitis.

Authors:  G J van Asselt; R P Mouton; C P van Boven
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-02       Impact factor: 3.267

5.  Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections.

Authors:  J K James; S M Palmer; D P Levine; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

6.  Antimycoplasmal activities of new quinolones, tetracyclines, and macrolides against Mycoplasma pneumoniae.

Authors:  S Arai; Y Gohara; K Kuwano; T Kawashima
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

7.  Polymyxin Combination Therapy and the Use of Serum Bactericidal Titers in the Management of KPC-Producing Klebsiella pneumoniae Infections: A Report of 3 Cases.

Authors:  Eric Gomez; Martha Sanchez; Zonaira Gul; Carl Urban; Noriel Mariano; Robert H K Eng; David B Huang; Tom Chiang
Journal:  Case Rep Med       Date:  2011-11-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.